Natera touts data supporting personalized ctDNA testing

LabPulse.com staff writers
Jul 6, 2020
2019 10 09 17 32 0093 Dna Cancer Cell 400

Natera is highlighting clinical data that supports the efficacy of personalized circulating tumor DNA (ctDNA) testing for oligometastatic colorectal cancer.

The data were presented at the virtual European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer, which was held from July 1 to 4, and support the validity of Natera's Signatera ctDNA test for identifying molecular residual disease in patients with this type of cancer. The test is customized for each individual, based on the clonal mutations in his or her tumor, according to the company.

A prospective trial in progress will measure clinical outcomes of molecular residual disease-guided treatment in oligometastatic colorectal cancer patients with stage II to III disease, Natera said.

Latest in Gastrointestinal Disease
Digestive System 3 D Intestine Social
Ingestible ‘smart pill’ may pinpoint GI disorders
February 13, 2023
Visit our Molecular Diagnostics Community
Sponsored
Visit our Molecular Diagnostics Community
April 5, 2024
2022 04 22 17 54 4420 Business Handshake Man 400
Pharos Capital sells TechLab to SSI Diagnostica
August 21, 2022
2022 07 15 19 56 0503 Genetics Dna Money 400
DiaSorin first-half revenues surge on non-COVID testing
August 3, 2022
Related Stories
2019 09 16 18 27 8672 Quality Check Mark 400
Companion Diagnostics
FDA approves new uses for Natera's MRD test
2019 04 19 17 00 9820 Fetus Mri 400
Collaboration
Natera prenatal test gets extended insurance coverage
2019 11 04 19 56 0311 Colorectal Cancer 400
Colorectal Cancer
Natera wins Medicare coverage for colorectal cancer test
Visit our Molecular Diagnostics Community
Sponsor Content
Visit our Molecular Diagnostics Community
More in Gastrointestinal Disease
Ingestible ‘smart pill’ may pinpoint GI disorders
By Elissa Wolfson
An ingestible smart pill uses magnetic fields to track its movement through the GI tract, potentially facilitating the treatment of GI motility disorders.
February 13, 2023
Digestive System 3 D Intestine Social
Thermo Fisher Scientific launches CE-IVD marked panel to detect most common gastrointestinal bacteria
By LabPulse.com staff writers
With results available in about two hours at greater than 98% sensitivity and specificity, the panel compares favorably with the culturing of samples in a lab, which can take up to two weeks, the firm said.
October 10, 2022
Diagnostic Analyzer Lab Pcr
Pharos Capital sells TechLab to SSI Diagnostica
By LabPulse.com staff writers
TechLab produces tests for infectious diseases, intestinal inflammation, and parasites, as well as gastrointestinal conditions such as inflammatory bowel disease, irritable bowel syndrome, and Escherichia coli infection. It also offers a test for Clostridioides difficile called Quik Chek, according to Pharos Capital.
August 21, 2022
2022 04 22 17 54 4420 Business Handshake Man 400
DiaSorin first-half revenues surge on non-COVID testing
By LabPulse.com staff writers
Revenues were driven in part by sales of products from Luminex, acquired last July for $1.8 billion.
August 3, 2022
2022 07 15 19 56 0503 Genetics Dna Money 400
Guardant touts studies on liquid biopsy tests at ASCO meeting
By LabPulse.com staff writers
Data from a large, prospective, observational study shows that Guardant Reveal can detect molecular residual disease (MRD) prior to disease recurrence with an average lead time greater than six months when performed after curative intent surgery for stage II-III colorectal cancer, Guardant said.
January 19, 2022
2020 06 01 18 51 2022 Cancer Lung 400
How will the Quidel, Ortho deal impact the point-of-care market?
By Bruce Carlson
The company that can impact the point-of-care market drives the future. The COVID-19 pandemic made that point visible, but the point-of-care sector was always significant, even before the pandemic. Point-of-care markets (and the companies that served them) grew faster than other markets.
January 3, 2022
2021 12 30 00 31 3981 Business Graph Money Stocks 400
More stool PCR testing likely needed in COVID-19 patients
By Emily Hayes
COVID-19 is commonly seen as a respiratory disease and much of the focus for diagnosis and also discharge of patients from hospitals following recovery has understandably been on the status of respiratory specimens. But gastrointestinal symptoms are also part of the disease and deserve more attention to help "prevent further spread of this highly contagious pathogen," wrote Dr. Sravanthi Parasa, a gastroenterologist at Swedish Medical Center in Seattle, and colleagues.
June 11, 2020
2020 06 10 23 20 5069 Stomach And Medical Icon 400
Jury is still out on SARS-CoV-2 intermediate host
By Samantha Black, PhD
One researcher from the University of Ottawa provides genomic evidence that dogs may be an intermediate carrier, while another study from Chinese researchers suggests that canines would be a poor transmitter of the virus.
April 16, 2020
2020 04 17 17 26 9580 Dog Field Stray 400
Meridian acquires GenePOC from Debiopharm
By LabPulse.com staff writers
Through the deal, Meridian will gain GenePOC's revogene product for microbial testing, which incorporates polymerase chain reaction (PCR) techniques for rapid testing in cases where infectious diseases are suspected. The product is marketed in the U.S., Europe, and Canada.
April 30, 2019
2019 04 30 22 11 5866 Bacteria 400
Page 1 of 1